1 |
Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 1996;93:848-52.
DOI
|
2 |
Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium- dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1321-7.
DOI
|
3 |
Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992;20:175-80.
DOI
|
4 |
Sung MJ, Kim W, Ahn SY, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005;97:880-90.
DOI
|
5 |
Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.
DOI
|
6 |
Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997;38:79-101.
|
7 |
Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-301.
DOI
|
8 |
Lee KM, Park KG, Kim YD, et al. Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery. Atherosclerosis 2006;189:106-14.
DOI
|
9 |
Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993;90:6189-93.
DOI
|
10 |
Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993;21:221-7.
DOI
|
11 |
Sung CP, Arleth AJ, Eichman C, Truneh A, Ohlstein EH. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 1997;283:910-7.
|
12 |
Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132(1 Pt 1):23-9.
DOI
|
13 |
Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
DOI
|
14 |
Pfuetze KD, Dujovne CA. Probucol. Curr Atheroscler Rep 2000;2:47-57.
DOI
|
15 |
Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72.
DOI
|
16 |
Cote G, Tardif JC, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 1999;99:30-5.
DOI
|
17 |
Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 1993;88:628-37.
DOI
|
18 |
Wasserman MA, Sundell CL, Kunsch C, Edwards D, Meng CQ, Medford RM. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003;91:34A-40A.
DOI
|
19 |
Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107: 552-8.
DOI
|
20 |
Liu Q, Ding J, Mante FK, Wunder SL, Baran GR. The role of surface functional groups in calcium phosphate nucleation on titanium foil: a self-assembled monolayer technique. Biomaterials 2002;23:3103-11.
DOI
|
21 |
Wakeyama T, Ogawa H, Iida H, et al. Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 2003;67:519-24.
DOI
|
22 |
Logeart D, Prigent-Richard S, Jozefonvicz J, Letourneur D. Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization. Eur J Cell Biol 1997;74:376-84.
|
23 |
Kim JM, Cho EJ, et al. Effect of fucoidan for smooth muscle cell proliferation and neointima hyperplasia in a rabbit iliac artery in-stent restenosis model. Korean Circ J 2011;41:II-245. Abstract.
|
24 |
Fu J, Ji J, Yuan W, Shen J. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials 2005;26:6684-92.
DOI
|
25 |
Meng S, Liu Z, Shen L, et al. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 2009;30:2276-83.
DOI
|
26 |
Lee H, Dellatore SM, Miller WM, Messersmith PB. Mussel-inspired surface chemistry for multifunctional coatings. Science 2007;318:426-30.
DOI
|
27 |
Rich DH, Singh J. The Carbodiimide Method. In: Meienhofer, editor. The peptides. Acadenic Press;1979. p.241-61.
|
28 |
Tsyganov I, Maitz MF, Wieser E, Richter E, Reuther H. Correlation between blood compatibility and physical surface properties of titanium-based coatings. Surf Coat Technol 2005;200:1041-4.
DOI
|
29 |
Bae IH, Park IK, Park DS, Lee H, Jeong MH. Thromboresistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface. J Mater Sci Mater Med 2012;23:1259-69.
DOI
|
30 |
Song SJ, Park YJ, Park J, et al. Preparation of a drug-eluting stent using a TiO2 film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix. J Mater Chem 2010;20:4792-801.
DOI
|
31 |
Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium- nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001;104:928-33.
DOI
|
32 |
Puskas JE, Muñoz-Robledo LG, Hoerr RA, et al. Drug-eluting stent coatings. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:451-62.
DOI
|
33 |
Song SJ, Jung KW, Park YJ, et al. Nitrogen-doped TiO2 films as drugbinding matrices for the preparation of drug-eluting stents. J Mater Chem 2011;21:8169-77.
DOI
|
34 |
Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50.
DOI
|
35 |
Sim DS, Kwon JS, Kim YS, et al. Experience with Endothelial Progenitor Cell Capturing Aptamers for Coating of Intracoronary Stents in a Porcine Model. TERM 2009;6:555-61.
|
36 |
Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.
DOI
|
37 |
Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel- eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
DOI
|
38 |
Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
DOI
|
39 |
Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21.
DOI
|
40 |
Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimuseluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
DOI
|
41 |
Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012;125:1246-55.
DOI
|
42 |
Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimuseluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimuseluting stent Trial (RESET). Circulation 2012;126:1225-36.
DOI
|
43 |
Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010;3:1043-50.
DOI
|
44 |
Lim SY, Bae EH, Jeong MH, et al. Effect of alpha lipoic acid in a porcine in-stent restenosis model. J Cardiol 2009;54:375-85.
DOI
|
45 |
Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010;56:1187-95.
DOI
|
46 |
Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91.
DOI
|
47 |
Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-405.
DOI
|
48 |
Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease. Korean J Intern Med 2004;19:220-9.
DOI
|
49 |
Kim W, Jeong MH, Kim KH, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006;47:933-8.
DOI
|
50 |
Hong YJ, Jeong MH, Hwang SH, et al. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis. Int J Cardiol 2007;123:23-8.
DOI
|
51 |
Kim JM, Kim JH, Jeong MH, et al. Fabrication and evaluation of a fucoidan- coated stent in a porcine coronary restenosis model. Korean Circ J 2012;42:II-120. Abstract.
|
52 |
Hong YJ, Jeong MH, Lee SR, et al. Anti-inflammatory effect of abciximab- coated stent in a porcine coronary restenosis model. J Korean Med Sci 2007;22:802-9.
DOI
|
53 |
Kim SS, Hong YJ, Jeong MH, et al. Two-year clinical outcome after abciximab- coated stent implantation in patients with coronary artery disease. Circ J 2010;74:442-8.
DOI
|
54 |
Hong YJ, Jeong MH, Song SJ, et al. Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. Korean Circ J 2011;41:535-41.
DOI
|
55 |
Lim KS, Hong YJ, Hachinohe D, et al. Effect of a dual drug-coated stent with abciximab and alpha-lipoic Acid in a porcine coronary restenosis model. Korean Circ J 2011;41:241-7.
DOI
|
56 |
Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87.
DOI
|
57 |
Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60.
DOI
|
58 |
Jiang HL, Hong SH, Kim YK, et al. Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy. Int J Pharm 2011;420:256-65.
DOI
|
59 |
Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22.
DOI
|
60 |
Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8.
DOI
|
61 |
Che HL, Bae IH, Lim KS, et al. Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model. Biomaterials 2012;33:8548-56.
DOI
|
62 |
Jere D, Arote R, Jiang HL, Kim YK, Cho MH, Cho CS. Biodegradable nano- polymeric system for efficient Akt1 siRNA delivery. J Nanosci Nanotechnol 2010;10:3366-9.
DOI
|
63 |
Jiang HL, Xu CX, Kim YK, et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 2009;30:5844-52.
DOI
|
64 |
Duguay D, deBlois D. Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. Br J Pharmacol 2007;151:1315-23.
|
65 |
Jere D, Jiang HL, Kim YK, et al. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int J Pharm 2009;378:194-200.
DOI
|
66 |
Kwon JC, Song SJ, Yang EJ, et al. Novel abciximab-Kruppel-like factor 4-plasmid dual-delivery titanium dioxide-coated coronary stent. Int J Cardiol 2013.
|
67 |
Bae Y, Jeong MH, Jang YS, et al. Comparison of porcine corinary stent restenosis between MAC (Maximum Arterial Re-Creation) and Palmaz-Schatz stent. Korean Circ J 1998;28:89-96.
|
68 |
Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
DOI
|
69 |
Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75.
DOI
|
70 |
Hong YJ, Jeong MH, Ahn Y, Kang JC. The efficacy and safety of drugeluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR). Int J Cardiol 2013;163:1-4.
DOI
|
71 |
Park KH, Jeong MH, Lee MG, et al. What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation? J Cardiol 2011;57:53-60.
DOI
|
72 |
Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty. Arch Pathol Lab Med 1985;109:173-5.
|
73 |
Ahn YK, Jeong MH, Kim JW, et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999;48:324-30.
DOI
|
74 |
Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14.
DOI
|
75 |
Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG editor. Basic & Clinical pharmacology. 12th ed. New York: McGraw Hill;2012. p.985-94.
|
76 |
Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: Elsevier Saunders;2012.
|
77 |
Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002;41:391-412.
|
78 |
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
DOI
|
79 |
Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000;86:385-9.
DOI
|
80 |
Kim YJ, Kang IK, Huh MW, Yoon SC. Surface characterization and in vitro blood compatibility of poly (ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge. Biomaterials 2000;21:121-30.
DOI
|
81 |
Chen H, Chen Y, Sheardown H, Brook MA. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials 2005;26:7418-24.
DOI
|
82 |
Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-91.
DOI
|
83 |
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
DOI
|
84 |
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
DOI
|
85 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
DOI
|
86 |
Mickelson JK, Ali MN, Kleiman NS, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;33:97-106.
DOI
|
87 |
Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98:863-74.
DOI
|
88 |
Shappell SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 1990; 144:2702-11.
|
89 |
Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.
DOI
|
90 |
Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996;17:9-18.
|